Zenas BioPharma Statistics
Total Valuation
ZBIO has a market cap or net worth of $418.33 million. The enterprise value is $31.91 million.
Important Dates
The next estimated earnings date is Sunday, February 16, 2025, before market open.
Earnings Date | Feb 16, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
ZBIO has 41.79 million shares outstanding. The number of shares has increased by 103.87% in one year.
Current Share Class | 41.79M |
Shares Outstanding | 41.79M |
Shares Change (YoY) | +103.87% |
Shares Change (QoQ) | +391.15% |
Owned by Insiders (%) | 0.79% |
Owned by Institutions (%) | 54.18% |
Float | 26.92M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.16 |
P/TBV Ratio | 1.16 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.95, with a Debt / Equity ratio of 0.00.
Current Ratio | 8.95 |
Quick Ratio | 8.79 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.33% and return on invested capital (ROIC) is -38.80%.
Return on Equity (ROE) | -63.33% |
Return on Assets (ROA) | -34.13% |
Return on Capital (ROIC) | -38.80% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.13M |
Employee Count | 114 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, ZBIO has paid $301,000 in taxes.
Income Tax | 301,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 15.97 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 37.73 |
Average Volume (20 Days) | 583,712 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | -110.40M |
Operating Income | -133.04M |
Pretax Income | -54.46M |
Net Income | -128.97M |
EBITDA | -132.91M |
EBIT | -133.04M |
Earnings Per Share (EPS) | -$41.59 |
Full Income Statement Balance Sheet
The company has $386.80 million in cash and $384,000 in debt, giving a net cash position of $386.42 million or $9.25 per share.
Cash & Cash Equivalents | 386.80M |
Total Debt | 384,000 |
Net Cash | 386.42M |
Net Cash Per Share | $9.25 |
Equity (Book Value) | 359.44M |
Book Value Per Share | 8.60 |
Working Capital | 349.78M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$96.52 million and capital expenditures -$74,000, giving a free cash flow of -$96.59 million.
Operating Cash Flow | -96.52M |
Capital Expenditures | -74,000 |
Free Cash Flow | -96.59M |
FCF Per Share | -$2.31 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ZBIO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -103.87% |
Shareholder Yield | -103.87% |
Earnings Yield | -30.83% |
FCF Yield | -23.09% |
Dividend Details Analyst Forecast
The average price target for ZBIO is $31.75, which is 217.18% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $31.75 |
Price Target Difference | 217.18% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
ZBIO has an Altman Z-Score of 8.55 and a Piotroski F-Score of 2.
Altman Z-Score | 8.55 |
Piotroski F-Score | 2 |